The Effect of Hesperidin on Glucose / Insulin Metabolism

NCT02610491 | Completed Phase 2

• 1 other identifier: 143036
• Study Type: interventional
• Target: 53
• Locations: 1 country
• Sites: 1

Brief Summary

Metabolic Syndrome (MS) is a well-known group of obesity-related metabolic disorders including insulin resistance (IR), dyslipidemia and hypertension (HTN). In addition, overweight has a causal relationship with a chronic low grade systemic inflammatory condition and increased intestinal permeability. Over the last decade, this multiplex disorder has progressively become a major worldwide public health problem, because of its association with increased risk of type 2 diabetes mellitus (DM2), atherosclerotic cardiovascular disease and all-cause mortality. Scientific evidence for measures to improve cardiometabolic and intestinal health by non-pharmaceutical means are of urgent need. Administration of the flavonoid hesperidin to those at risk may have beneficial effects on glucose / insulin metabolism, lipid metabolism, blood pressure, heart rate, pro-inflammatory and oxidative stress biomarkers and gut barrier function. Objective: To determine the 12-week effect of daily administration of hesperidin on the main cardiometabolic disorders related to MS as assessed by investigation of glucose/insulin metabolism, blood lipid profile, blood pressure, heart rate, body composition and gut barrier function in subjects at risk for MS. Study design: This is a randomized, double-blind, placebo-controlled study with parallel design. Study population: Healthy (male/female) volunteers, age 18-65, at risk for metabolic syndrome (presenting with 2 out of 5 of the components from NCEP-ATP-III criteria). Intervention: Participants will be randomly assigned to one of the intervention groups. One group will receive one daily dose of hesperidin capsules while the other group receives identical looking placebo capsules for a period of 12 weeks. The capsules will have to be ingested with a glass of water every morning just before breakfast. Main study parameters/endpoints: The primary efficacy parameter of this study is the oral glucose tolerance test (OGTT), a validated surrogate endpoint to study the β-cell function and insulin sensitivity. Secondary endpoints entail the evaluation of effects of daily administration of hesperidin on lipid profile (blood measurements), blood pressure and heart rate, body composition, low-grade inflammation biomarkers (blood measurements) and gut barrier function (blood measurements, fecal samples, urine collection).

Conditions

Metabolic Syndrome; Obesity

Outcome Measures

Primary Outcomes (1)

• Effect on blood glucose concentrations measured by oral glucose tolerance test

  12 weeks

Secondary Outcomes (6)

• Effect on blood lipid profile

  12 weeks

• Effect on blood pressure

  12 weeks

• Effect on body composition measured by BMI

  12 weeks

• Effect on low-grade inflammation measured by blood concentration of TNFalfa

  12 weeks

• Effect on low-grade inflammation measured by blood concentration of interleukin-6

  12 weeks

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Cellulose

Dietary Supplement: Placebo

Hesperidin

ACTIVE COMPARATOR

Citrus peel extract

Dietary Supplement: Hesperidin

Interventions

Hesperidin DIETARY_SUPPLEMENT

Citrus peel extract

Hesperidin

Placebo DIETARY_SUPPLEMENT

Cellulose

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \* Subjects at risk for metabolic syndrome: a combination of 2 out of 5 components:
• Waist circumference: men \> 102 cm / women \> 88 cm
• Triglycerides: ≥ 1.7 mmol/l
• HDL-cholesterol: men ≤ 1.0 mmol/l / women ≤ 1.3 mmol/l
• Systolic blood pressure: ≥ 130 mmHg or diastolic blood pressure: ≥ 85 mmHg
• Fasted serum glucose ≥ 6.1 mmol/L

You may not qualify if:

• Type 2 diabetes mellitus (defined as fasting plasma glucose ≥7.0 mmol/l)
• Gastroenterological diseases or abdominal surgery
• Cardiovascular diseases, cancer, liver or kidney malfunction, thyroid disorders, disease with a life expectancy shorter than 5 years
• Self-admitted HIV-positive status
• Abuse of products; alcohol (\> 20 alcoholic consumptions per week) and drugs
• Smoking
• Plans to lose weight or following a hypocaloric diet during the study period
• Weight gain or loss \> 3 kg in previous 3 months
• Use of medication interfering with endpoints
• Use of antioxidants, minerals and vitamin supplements available in pharmacies, drugstores, food markets or in alternative medicine
• Hormone replacement therapy (women).
• Use of antibiotics in the 90 days prior to the start of study
• Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator) in the 180 days prior to the study
• Known pregnancy (assessed by a pregnancy test before start of study) or lactation
• Blood donation within 3 months before study period

Sponsors & Collaborators

• Maastricht University Medical Center: lead

Study Sites (1)

MUMC+

Maastricht, Limburg, 6221EG, Netherlands

Location

MeSH Terms

Conditions

Metabolic Syndrome; Obesity

Interventions

Hesperidin

Condition Hierarchy (Ancestors)

Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Flavanones; Flavonoids; Chromones; Benzopyrans; Pyrans; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Glycosides; Carbohydrates

Study Officials

• Ad Masclee, MD

  Maastricht University Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: November 16, 2015
• First Posted: November 20, 2015
• Study Start: February 1, 2015
• Primary Completion: October 1, 2015
• Study Completion: October 1, 2015
• Last Updated: November 20, 2015

Record last verified: 2015-11

Locations

NL (1)